Introduction {#Sec1}
============

Systemic hyperactivity of the sympathetic nervous system is a hallmark of chronic kidney disease (CKD) \[[@CR7], [@CR9], [@CR15]\]. Moreover, sympathetic nerve activity (SNA) is an independent predictor of kidney disease progression \[[@CR18]\]. Also, therapies that limit sympathetic nervous system activity have shown to improve kidney function \[[@CR7]\]. This has led to the pathophysiological paradigm that sympathetic activity is a causal factor in the progression of CKD \[[@CR15], [@CR18], [@CR20], [@CR27], [@CR30]\]. Central to the mechanism by which this occurs are the direct stimulation of profibrotic factors \[[@CR13]\] and the induction of hypoxia \[[@CR16], [@CR30]\], which is the topic of the current study.

The renal parenchyma is characterized by a steep pO~2~ gradient and is thereby susceptible to hypoxia \[[@CR5], [@CR21], [@CR22]\]. In animals, renal sympathetic activation decreases renal blood flow \[[@CR14]\]. Simultaneously, sympathetic nerves directly innervate the renal tubules, inducing sodium reabsorption and thus increasing metabolic demand \[[@CR3], [@CR21]\]. The net effect of decreased renal blood flow and increased tubular demand is therefore a decrease in oxygenation \[[@CR3], [@CR6], [@CR21]\]. However, direct observations of the effect of sympathetic activation on renal oxygenation in humans are lacking.

Lower body negative pressure (LBNP) can be used to experimentally increase systemic SNA in humans \[[@CR2], [@CR10], [@CR12]\]. Low-grade LBNP induces sustained sympathetic activation without systemic blood pressure effects \[[@CR12]\]. Moderate-grade LBNP induces further sympathetic activation with moderate hemodynamic effects while maintaining organ perfusion pressure \[[@CR10], [@CR26], [@CR28]\]. In the kidneys, LBNP reduces blood flow and the glomerular filtration rate while the glomerular filtration fraction (FF) remains unaffected \[[@CR8], [@CR28], [@CR33]\]. LBNP is therefore ideally suited to investigate sympathorenal effects on renal oxygenation.

Kidney oxygenation can reliably be assessed by blood oxygen level dependent (BOLD) MRI \[[@CR24], [@CR25]\]. As BOLD MRI is sensitive to the blood deoxyhemoglobin level, the acquired signal is the composite result of oxygen extraction from the blood (i.e., metabolic demand) and the rate of oxygen delivery (i.e., perfusion) \[[@CR17]\]. This technique was originally validated in a porcine model \[[@CR23]\]. The technique was also shown to provide excellent intra-individual tracking of minor changes in kidney oxygenation in subsequent human studies. For example, we showed a 5% decrease in cortical oxygenation during angiotensin II (Ang-II) infusion in healthy humans. These changes are caused by an Ang-II-driven increase in FF, i.e., increasing tubular workload relative to renal perfusion \[[@CR29]\].

There seems to be a conflict between two (patho)physiologic observations regarding the role of SNA in the kidney hypoxia. On the one hand, sympathetic activation decreases renal blood flow and increases tubular metabolic load, affecting renal oxygenation negatively \[[@CR6]\]. On the other hand, sympathetic activity does not alter FF \[[@CR8], [@CR28], [@CR33]\], thereby maintaining the balance between metabolic demand and oxygen supply. Against this background, we set out to explore the physiological effect of sympathetic activation by LBNP on cortical and medullary oxygenation by BOLD MRI in healthy human subjects. We hypothesized that with low to moderate grades of LBNP, renal blood flow and medullary oxygenation decreases, while cortical oxygenation is only affected at moderate-grade LBNP. In addition, we compared the renal oxygenation effects of LBNP to those induced by Ang-II using historic data.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

Eight healthy subjects were studied (age 19--31 years, 5/3 male/female, height 1.61--1.85 m, weight 62--76 kg). Their medical histories revealed no significant disease and none used medication. Written informed consent was obtained from all participants, and the study protocol (protocol number NL53367.018.15) was approved by the Medical Ethics Review Committee of the Academic Medical Center (METC AMC, Amsterdam, The Netherlands). The study was conducted in accordance with the Declaration of Helsinki 2013.

Study design {#Sec4}
------------

Kidney MRI was performed at baseline and during consecutive LBNP levels at − 15, − 30 mmHg, and recovery to 0 mmHg for 15 min each. The timeline of the protocol is given in Fig. [1](#Fig1){ref-type="fig"}. Based on data from previous studies \[[@CR8], [@CR28], [@CR33]\], the LBNP protocol was designed to reduce renal perfusion by LBNP to a similar extent to that achieved by continuous Ang-II infusion (0.3, 0.9 ng/kg/min) in our previous study of a different group of eight similarly healthy subjects (age 19--22 years, 5/3 male/female, height 1.61--1.90 m, weight 63--82 kg) with identical MRI acquisitions \[[@CR29]\]. This enabled comparison between the oxygenation responses of sympathetic activity (by LBNP) to Ang-II.Fig. 1Overview of the study design. **a** Timeline of the LBNP experiments, with the sequence of MRI acquisitions (*green* scout scan,*red* phase-contrast MRI,*orange* BOLD MRI). **b--d** Examples of the images acquired: scout scans with PC and BOLD MRI planning (**b**), velocity-encoded (*V*~enc~) map with segmented proximal renal artery (**c**), and R2\* map of coronal BOLD MRI slice with cortical and medullary segmentations (**d**)

After being instrumented with ECG electrodes and a brachial artery cuff, the subjects were placed in a custom-built LBNP box (Department of Medical Technology, LUMC, The Netherlands) mounted on the MRI table. The box had a fixed saddle and was sealed around the subjects' waists using a neoprene seal just above the iliac crest. Pillows, towels, and sandbags were used to provide a fully comfortable body position. An anterior MRI coil was secured over chest and abdomen. During the LBNP challenge, blood pressure and heart rate were monitored intermittently at ≥ 2-min intervals (Accutor Plus, Datascope Corp., USA). For subject safety, there was direct two-way audio communication with the LBNP vacuum pump and MRI operators. Also, a physician was present inside the MRI room to directly observe the subjects for signs of discomfort and/or presyncope.

Magnetic resonance imaging {#Sec5}
--------------------------

Magnetic resonance imaging was performed on a 3.0-T MRI system (Ingenia, Philips Healthcare, Best, Netherlands), as described previously \[[@CR29]\]. Survey scans, including 3D T1-weighted multi-echo gradient echo (T1 W GE) with Dixon reconstruction \[[@CR4]\], were used to locate the positions of the kidneys and renal arteries. To account for LBNP-associated motion of the subject, the Dixon-reconstructed survey scan was repeated at every LBNP dose. BOLD and phase-contrast (PC) MRI scans were subsequently acquired at baseline and during each LBNP dose.

Three-directional blood flow velocity was measured by PC MRI in a slice placed perpendicular to the right proximal renal artery, as described previously \[[@CR1], [@CR29]\]. In short, the PC MRI sequence parameters were as follows: the number of ECG-triggered cardiac phases was 30, field of view (FOV) = 200 × 200 mm, resolution = 0.65 × 0.65 mm^2^, slice thickness = 3 mm, repetition time (TR) /echo time (TE) = 8.5/5.7 ms, flip angle = 10°, SENSE factor = 2 (right-left direction), *V*~enc~ = 100 cm/s in all directions. Acquisition time was 3:45 min, and the sequence was acquired during free breathing. Offline image processing for PC MRI was performed using dedicated software (GTF low version 2.2.9, Gyro Tools LLC, Switzerland). After correcting for background phase-offset errors and aliasing, the mean RBF (mL/s) was calculated using manual vessel segmentation in each cardiac phase. For further RBF analysis, equal perfusion of both the right and the left kidneys was assumed \[[@CR11]\].

Changes in the BOLD MRI signal were quantitatively assessed by measuring the transverse relaxation rate (R2\*) within different regions of interest (ROIs). We measured R2\* using a multi-echo single-slice gradient-echo MRI sequence with the following parameters: FOV = 400 × 400 mm^2^, resolution = 1.2 × 1.2 mm^2^, slice thickness = 4 mm, TR = 140 ms, flip angle = 70°, TE~1~ = 2 ms, ΔTE = 5 ms; number of echoes = 16 \[[@CR25]\]. Image acquisition was performed in 18 s during a single expiratory breath hold in a coronal slice where the kidney cross-section was largest and cortical/medullary definition was best on the survey scans. For BOLD MRI analysis, circular ROIs with a diameter of eight voxels were defined at regular intervals throughout each kidney's cortex and medulla in the baseline scan. For each subject, the resulting masks were then transferred to the three subsequent BOLD images. Renal R2\* values were calculated for cortex and medulla separately, using monoexponential fits \[[@CR25], [@CR29]\] obtained with routines written in Matlab (The MathWorks, Natick, USA).

Study power and statistical analysis {#Sec6}
------------------------------------

The study was powered based on previous data using the same MRI protocols in healthy humans \[[@CR29]\]. In that study, we found that a 20% perfusion reduction resulted in a 2.4 s^−1^ increase in cortical R2\*. Anticipating a potentially reduced effect or potentially more variance in the current experiment, this study was powered at 0.81 to detect an R2\* increase of 1.4 s^−1^ in *n* = 8.

All data are presented as the mean with the standard error. Renal vascular resistance (RVR) was calculated as the mean arterial pressure (MAP) divided by the renal blood flow (RBF). The Shapiro--Wilk test was used to verify that the data were distributed normally. One-way ANOVA for repeated measures was used to assess the dose effect of LBNP on systemic hemodynamic effects (blood pressure, heart rate) and renal (RVR, RBF) hemodynamic parameters as well as cortical and medullary R2\*. A *Z*-test was used to compare the LBNP response to the historic positive control (Ang-II response). The *z*-score is reported with a two-tailed *p* value. All statistical analyses were performed using SPSS Statistics 22 (IBM, Chicago, USA). A significance level of *α* = 0.05 was used.

Results {#Sec7}
=======

Subjects {#Sec8}
--------

All subjects tolerated the LBNP doses well and reported no periods of discomfort or lightheadedness. Baseline measurements are given in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics per subjectSubject (\#, ♂/♀)HemodynamicsMRIMAP (mmHg)HR (bpm)RVR (mL/min/mmHg)CR2\* (s^−1^)MR2\* (s^−1^)RBF (mL/min)1, ♂79660.06420.233.012292, ♂85820.05917.024.914303, ♀81650.06518.629.512424, ♀83670.08224.025.910155, ♂81770.09321.427.58696, ♂86640.06017.629.914387, ♀98860.1117.925.88568, ♂87610.07726.232.01133Mean (SEM)85 (2.1)71 (3.3)0.076 (0.0063)20.3 (1.1)28.6 (1.0)1152 (75)Baseline characteristics after 15 min of supine rest*bpm* beats per minute, *CR2\** cortical R2\*, *HR* heart rate, *MAP* mean arterial pressure, *MR2\** medullary R2\*, *MRI* magnetic resonance imaging, *RBF* renal blood flow, *RVR* renal vascular resistance

Systemic hemodynamic changes induced by LBNP {#Sec9}
--------------------------------------------

The absolute values of the hemodynamic parameters during each stage of the experiment are listed in Table [2](#Tab2){ref-type="table"}. Figure [2](#Fig2){ref-type="fig"} depicts the responses in percentage change compared to baseline. As expected, the arterial blood pressure did not change significantly at the chosen levels of LBNP. Only the pulse pressure decreased significantly, from 50 ± 3.5 at baseline to 43 ± 2.3 mmHg at − 30 mmHg, *F*~(2,14)~ = 6.4, *p* = 0.043 (Fig. [2](#Fig2){ref-type="fig"}a). The heart rate increased by 38% ± 15% at maximum LBNP (*F*~(2,14)~ = 20.1, *p* = 0.004, Fig. [2](#Fig2){ref-type="fig"}b). These hemodynamic effects were present in all individual subjects. The LBNP intervention did not induce (pre)syncope in any of the subjects.Table 2Effects of LBNPHemodynamicsMRISBP (mmHg)DBP (mmHg)MAP (mmHg)PP (mmHg)HR (bpm)RVR (mL/min/mmHg)CR2\* (s^−1^)MR2\* (s^−1^)RBF (mL/min)Baseline118 (3.3)69 (2.1)85 (2.0)50 (3.5)71 (3.1)0.076 (0.0063)20.3 (1.1)28.6 (1.0)1152 (75)LBNP − 15 mmHg114 (2.8)68 (2.3)83 (2.1)47 (2.7)76 (2.6)0.083 (0.0057)19.6 (0.84)28.0 (1.8)1039 (72)LBNP − 30 mmHg115 (2.6)72 (1.9)86 (1.9)43 (2.3)\*90 (2.6)\*0.094 (0.0067)\*19.8 (0.40)28.0 (1.2)950 (63)\*Recovery116 (2.9)70 (2.0)85 (2.0)45 (2.6)72 (2.3)0.088 (0.0073)19.6 (0.56)26.5 (0.88)1012 (68)*bpm* beats per minute, *CR2\** cortical R2\*, *HR* heart rate, *MAP* mean arterial pressure, *MR2\** medullary R2\*, *MRI* magnetic resonance imaging, *PP* pulse pressure, *RBF* renal blood flow, *RVR* renal vascular resistance\*Indicates significant response to LBNPFig. 2Systemic and renal hemodynamic effects of low- to moderate-grade LBNP.**a** Mean arterial pressure/pulse pressure.**b** Heart rate.**c** Renal vascular resistance.**d** Renal blood flow.**e** Cortical R2\*.**f** Medullar R2\*. All graphs depict the percent change compared to baseline (BL) at − 15mmHg LBNP, − 30 mmHg LBNP, and during recovery (*RC*). Graphs depict the results of the current study in*black* and the results of our previous study using Ang-II infusion in*gray*, for comparison. That study assessed the same parameters as a function of the continuous infusion of Ang-II. Significant responses as assessed by repeated-measures ANOVA are indicated by \* and † for LBNP and Ang-II infusion, respectively \[[@CR28]\]

Renal perfusion and oxygenation {#Sec10}
-------------------------------

The absolute values of MRI-derived perfusion and oxygenation parameters during each stage of the experiment are listed in Table [2](#Tab2){ref-type="table"}. Figure [2](#Fig2){ref-type="fig"} depicts the responses in percentage change compared to baseline. Renal vascular resistance increased as a function of LBNP level by 23 ± 8% at − 30 mmHg LBNP (*F*~(2,14) ~= 27.8, *p* = 0.002, Fig. [2](#Fig2){ref-type="fig"}c). RBF decreased by 17% ± 2% at − 30 mmHg LBNP, *F*~(2,14) ~= 11.8, *p* = 0.013, Fig. [2](#Fig2){ref-type="fig"}d, black line). These renal hemodynamic effects were observed in all individual subjects. Neither the cortical R2\* (CR2\*) nor the medullary R2\* (MR2\*) changed during LBNP (Fig. [2](#Fig2){ref-type="fig"}e, f, black lines).

LBNP compared to Ang-II response {#Sec11}
--------------------------------

In a previous study, we performed an experiment similar to the current study using Ang-II infusion. The data from that experiment are depicted in gray in Fig. [2](#Fig2){ref-type="fig"} to aid comparison of the different effects of these interventions. In the Ang-II study, we measured perfusion and R2\* changes induced by 0.3 and 0.9 ng/kg/min Ang-II infusion in healthy volunteers \[[@CR29]\]. In those experiments, RBF showed an Ang-II dose-dependent decrease from 1215 ± 83 to 1025 ± 89 mL/min (Fig. [2](#Fig2){ref-type="fig"}d, gray line) and cortical R2\* increased from 17.4 ± 1.1 to 19.3 ± 0.8 s^−1^ (Fig. [2](#Fig2){ref-type="fig"}e, gray line). The average cortical R2\* response was *β* = 0.025 ± 0.17 in the LBNP group and *β* = 5.9 ± 2.4 in the Ang-II group; these responses were significantly different, with a *z*-score of *z* = 2.5 and a two-tailed *p* value of *p* = 0.014.

Discussion {#Sec12}
==========

Our findings can be summarized as follows. LBNP consistently increased heart rate and lowered pulse pressure, while organ perfusion pressure (MAP) was unchanged in all subjects. This is consistent with selective sympathetic activation. LBNP induced a marked increase in renal vascular resistance and reduced renal perfusion substantially in all subjects. However, during selective sympathetic activation, there was no discernible effect on kidney oxygenation in the cortex or medulla. This is in contrast to the decreased cortical oxygenation upon Ang-II infusion, with similar changes in renal vascular resistance and flow. These explorative data do not support sympathetic activity as a causal factor of renal hypoxia under physiological circumstances.

In light of the two conflicting concepts regarding the possible influences of SNA on renal oxygenation (decreased RBF with increased metabolic load vs. a maintained FF and oxygenation balance), we observe the following. During our LBNP experiments, we found a renal vascular resistance increase and a perfusion reduction that were virtually identical to those found by other authors in previous studies involving healthy humans \[[@CR8], [@CR28], [@CR32], [@CR33]\]. In those studies, both ERPF and GFR (as assessed by radioisotope measurements) decreased proportionally by approximately 10 and 20% at − 15 and − 30 mmHg, respectively, while FF was maintained. Applying those observations to our study, we infer that the oxygenation balance was maintained, which explains the absence of an effect of LBNP-induced sympathetic activation on renal oxygenation. This is further supported by Würzner et al., who also reported that the fractional distal reabsorption of sodium was unaffected during LBNP \[[@CR33]\]. Distal sodium reabsorption in the medullary thick ascending limb of Henle's loop is metabolically demanding \[[@CR21]\], and it seems that this process is also affected by LBNP in proportion to the renal perfusion reduction \[[@CR33]\]. Thus, the two processes with the most influence on renal oxygenation status, i.e., filtration fraction and distal sodium reabsorption, are affected in the same direction and to an equal extent to the RBF reduction during LBNP. This would suggest that sympathetic activation per se does not influence renal oxygenation in healthy humans.

Despite the known intricate interplay between the sympathetic nervous system and the renin angiotensin system (RAS), the current observations stand in contrast to the effects of Ang-II on renal oxygenation. Contrary to direct sympathetic neural activation, Ang-II directly changes the balance between oxygen supply and demand through vasoconstriction of the efferent arterioles of the glomerulus. Ang-II thereby decreases renal perfusion while metabolic demand is maintained \[[@CR29]\].

This is the first study to directly measure renal oxygenation during sympathetic activation in healthy humans. We successfully used a LBNP intervention as a sympathetic stimulus, in combination with renal MRI measurements. Although the imaging area was in close proximity to the LBNP box, we did not observe any distortion in the MR images. The premise of this study was a universal physiological phenomenon. The lack of an effect on cortical and medullary R2\* may suggest a potential type II statistical error. We acknowledge that the small sample size is the most important limitation of our study. However, a post hoc power calculation for the point estimate from the current study showed that number of subjects needed to achieve a statistical power of 80% to consolidate this effect is 209. Apart from the questionable relevance of such a minor effect, it is not feasible to include this number of subjects. We speculate that, in CKD patients, the effects may be discernable in smaller sample sizes.

A limitation related to the small sample size is the lack of a comparison between males and females. Although each subject is its own control, effects of male/female differences may be reflected in the variation within the results. Other limitations of our study concern the absence of direct verification of an increased sympathetic tone (e.g., by microneurography) and the degree of sodium retention during the experiments. However, these effects have been extensively documented \[[@CR8], [@CR10], [@CR12], [@CR26], [@CR28], [@CR33]\], and combining these measurements with MRI is not (yet) feasible. Another limitation is that we cannot rule out that other factors were superimposed on the sympathetic neural activation. Specifically, we did not measure hormones that regulate renal hemodynamics, while it is known that RAS activation and renal noradrenaline spillover occur at medium-grade LBNP. It has been documented that 10 min of a LBNP of − 18 mmHg or lower induces detectable increases in plasma renin activity and Ang-II levels \[[@CR28]\]. Renal noradrenaline spillover has been shown to increase in conjunction with sympathetic nerve activity \[[@CR19]\]. Possibly, RAS activation and/or noradrenaline spillover is reflected in the delayed return to baseline in renal perfusion and renal vascular resistance after LBNP cessation that we observed. In these experiments, the RAS activation kinetics induced by LBNP may have been different or insufficient to induce renal hypoxia. Another possible underlying effect of LBNP that may be involved in the described mechanisms is the difference in response between cardiac and renal sympathetic outflow. It has been shown in sheep that organ-specific responses are regulated through different neural pathways \[[@CR31]\]. Our results cannot discern between those specific neural effects. In general, MR imaging may affect sympathetic tone due to the confined surroundings, movement restriction, loud noises, and end-expiratory breath holds required for BOLD-MRI. However, these circumstances were constant during all stages of the experiments and their effects on individual outcomes were expected to be minimal, and none of the subjects suffered from claustrophobia. Lastly, the data from a previous experiment presented in the results and discussed above were obtained from a different group of subjects who had been recruited from the same population as the subjects in the current study.

Regarding the generalizability of our results to CKD patients, we are limited by the fact that this constitutes an acute experiment in a small group of young healthy subjects versus a chronic pathophysiological process observed in patients. However, a chronically sustained sympathetic activating intervention is not feasible in humans. Whether the renal oxygenation response to LBNP is different in patients should be explored in further studies.

In conclusion, our exploratory data question the universal physiological concept that sympathetic hyperactivity per se decreases kidney oxygenation. We showed that selective induction of sympathetic activity by LBNP induces a substantial and consistent renal blood flow reduction without parallel cortical or medullary hypoxia. These data are in agreement with the notion that sympathetic activation suppresses renal oxygen demand and supply equally, thus maintaining adequate tissue oxygenation.
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